Please login to the form below

Not currently logged in
Email:
Password:

Alexion Pharma

This page shows the latest Alexion Pharma news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The drug currently accounts for more than 80% of Alexion’s sales, but is

Latest news

  • Bluebird and Alexion veterans launch cell and gene venture ElevateBio Bluebird and Alexion veterans launch cell and gene venture ElevateBio

    Massachusetts. The company was unveiled yesterday by its co-founders David Hallal and Vikas Sinha, previously last chief exec and chief financial officer respectively of Alexion, with ex-Bluebird Bio chief ... Hallal and Sinha left Alexion under a cloud

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Dova Pharma’s Doptelet (avatrombopag) for the treatment of

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.

  • Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion adds to pipeline with $1.2bn Syntimmune buy

    Alexion has agreed a $1.2bn takeover of US biotech Syntimmune that will add another clinical-stage rare disease drug to its R&D pipeline. ... in the early stages of growth – Alexion has been fixated on bolstering its pipeline.

  • Alexion uses priority review voucher for Soliris follow-up Alexion uses priority review voucher for Soliris follow-up

    Files ravulizumab for paroxysmal nocturnal haemoglobinuria. Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted ... Alexion says it is planning additional regulatory

More from news
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to

  • Alexion Pharmaceutiacal names interim CEO and CFO Alexion Pharmaceutiacal names interim CEO and CFO

    suited to lead Alexion as we embark on our next exciting phase of growth. ... We are also delighted that Dave Anderson is joining Alexion as our new chief financial officer.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....
Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...

Infographics